Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
Edgewise to Present at the Leerink Partners Global Biopharma Conference
Edgewise to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy
Edgewise Reports Fourth Quarter and Full Year 2023 Financial Results
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506
Edgewise Announces Pricing of $240 Million Underwritten Offering of Common Stock
Edgewise Highlights 2023 Accomplishments and Anticipated Milestones for 2024